Medtronic PLC $MDT Shares Sold by SVB Wealth LLC

SVB Wealth LLC trimmed its stake in Medtronic PLC (NYSE:MDT) by 17.7% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 27,552 shares of the medical technology company’s stock after selling 5,942 shares during the quarter. SVB Wealth LLC’s holdings in Medtronic were worth $2,155,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Madison Asset Management LLC raised its position in shares of Medtronic by 15.0% in the 4th quarter. Madison Asset Management LLC now owns 195,216 shares of the medical technology company’s stock worth $18,752,000 after buying an additional 25,527 shares during the period. Gradient Investments LLC grew its position in Medtronic by 3.9% during the second quarter. Gradient Investments LLC now owns 496,513 shares of the medical technology company’s stock valued at $38,842,000 after acquiring an additional 18,509 shares during the period. Czech National Bank increased its stake in Medtronic by 4.7% during the second quarter. Czech National Bank now owns 365,443 shares of the medical technology company’s stock worth $28,589,000 after acquiring an additional 16,292 shares during the last quarter. Cerity Partners LLC increased its stake in Medtronic by 12.7% during the fourth quarter. Cerity Partners LLC now owns 791,015 shares of the medical technology company’s stock worth $75,988,000 after acquiring an additional 89,111 shares during the last quarter. Finally, National Pension Service raised its holdings in shares of Medtronic by 1.0% in the 4th quarter. National Pension Service now owns 2,982,411 shares of the medical technology company’s stock worth $286,490,000 after purchasing an additional 28,269 shares during the period. Institutional investors and hedge funds own 82.06% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. TD Cowen boosted their target price on Medtronic from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Friday, August 28th. UBS Group raised their price target on shares of Medtronic from $100.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, September 3rd. Weiss Ratings raised shares of Medtronic from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, September 4th. Wall Street Zen downgraded shares of Medtronic from a “buy” rating to a “hold” rating in a research note on Saturday, September 5th. Finally, Bank of America increased their price objective on shares of Medtronic from $95.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, September 2nd. Nineteen research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Medtronic presently has a consensus rating of “Moderate Buy” and an average target price of $103.92.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic raised its fiscal 2027 organic revenue-growth outlook and increased the lower end of its adjusted earnings forecast after quarterly results exceeded expectations. Cardiovascular devices were the primary growth engine, while surgical products also contributed to broad-based expansion. Medtronic Raised its Outlook as Heart Devices Accelerate, But Can the Momentum Last?
• Positive Sentiment: Recent results showed 13.7% year-over-year revenue growth, $9.76 billion in quarterly revenue versus a $9.55 billion consensus estimate, and adjusted EPS of $1.45 versus expectations of $1.39. The performance suggests improving demand across Medtronic’s cardiovascular and surgical franchises. Medtronic Q1 2027 Earnings Call Transcript
• Positive Sentiment: Medtronic remains attractive to income-focused investors, offering a roughly 3% dividend yield and having increased its dividend for 49 consecutive years. The company is potentially two years away from reaching “Dividend King” status, which could support long-term shareholder interest. Medtronic Is on the Cusp of Becoming a Dividend King
• Neutral Sentiment: Analysts view the improved growth and earnings outlook favorably, but investors remain selective because Medtronic must demonstrate that its cardiovascular acceleration is sustainable beyond the latest quarter.
• Negative Sentiment: Margin pressure, foreign-exchange effects, execution risks and intense medical-device competition could limit the benefit of stronger sales growth. These concerns help explain why the stock has not fully reflected the improved outlook. Medtronic Raises 2027 Outlook as Broad-Based Growth Gains Momentum

Medtronic Stock Performance

Shares of MDT stock opened at $92.01 on Thursday. Medtronic PLC has a 12 month low of $73.31 and a 12 month high of $106.33. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.07 and a quick ratio of 1.54. The firm has a market capitalization of $117.69 billion, a P/E ratio of 22.66, a P/E/G ratio of 2.17 and a beta of 0.56. The company’s fifty day moving average price is $87.58 and its two-hundred day moving average price is $85.17.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, beating the consensus estimate of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%.The company had revenue of $9.76 billion during the quarter, compared to the consensus estimate of $9.55 billion. During the same period last year, the firm earned $1.26 earnings per share. The company’s revenue was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, research analysts anticipate that Medtronic PLC will post 5.96 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 16th. Shareholders of record on Friday, September 25th will be given a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date of this dividend is Friday, September 25th. Medtronic’s dividend payout ratio is presently 70.94%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops, manufactures and sells devices and therapies used to diagnose and treat a broad range of medical conditions. Its products are designed for hospitals, physicians and patients across areas including cardiac care, diabetes, neurological disorders, spinal conditions and surgical procedures.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, heart valves, neurostimulation systems, implantable pumps, spinal implants and surgical technologies.